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Abstract
PURPOSE: The present systematic review aimed to identify prognostic values of tissue-based biomarkers in patients treated with neoadju-
vant systemic therapy (NAST), including chemotherapy (NAC) and checkpoint inhibitors (NAI) for urothelial carcinoma of the bladder (UCB).
MATERIAL AND METHODS: The PubMed, Web of Science, and Scopus databases were searched in August 2020 according to the
PRISMA statement. Studies were deemed eligible if they compared oncologic or pathologic outcomes in patients treated with NAST for
UCB with and without detected pretreatment tissue-based biomarkers.
RESULTS: Overall, 44 studies met our eligibility criteria. Twenty-three studies used immunohistochemistry (IHC), 19 − gene expres-
sion analysis, three - quantitative polymerase chain reaction (QT PCR), and two − next-generation sequencing (NGS). According to the cur-
rently available literature, predictive IHC-assessed biomarkers, such as receptor tyrosine kinases and DNA repair pathway alterations, do
not seem to convincingly improve our prediction of pathologic response and oncologic outcomes after NAC. Luminal and basal tumor sub-
types based on gene expression analysis showed better NAC response, while claudin-low and luminal-infiltrated tumor subtypes did not. In
terms of NAI, PD-L1 seems to maintain value as a predictive biomarker, while the utility of both tumor mutational burden and molecular
subtypes remains controversial. Specific genomic alterations in DNA repair genes have been shown to provide significant predictive value*Corresponding Author. Department of Urology, Comprehensive Cancer
Center, Vienna General Hospital, Medical University of Vienna,
W€ahringer G€urtel 18-20, 1090, Vienna, Austria. Tel.: +4314040026150;
fax: +4314040023320
E-mail address: shahrokh.shariat@meduniwien.ac.at (S.F. Shariat).
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E. Laukhtina et al. / Urologic Oncology: Seminars and Original Investigations 39 (2021) 180−190 181in patient treated with NAC. QT PCR quantification of specific genes selected through microarray analysis seems to classify cases regarding
their NAC response.
CONCLUSION: We believe that the present systematic review may offer a robust framework that will enable the testing and validation
of predictive biomarkers in future prospective clinical trials. NGS has expanded the discovery of molecular markers that are reflective of
the mechanisms of the NAST response.  2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/)Keywords: Biomarkers; UCB; bladder cancer; Neoadjuvant systemic therapy; NAC; systematic review1. Introduction
Urothelial carcinoma of the bladder (UCB) is one of the
most frequently diagnosed and harmful cancers worldwide
[1]. Neoadjuvant cisplatin based combination chemotherapy
(NAC) prior to radical cystectomy is the preferred first treat-
ment in cisplatin eligible patients with muscle-invasive UCB
[2, 3]. However, multiple reasons impeded the widespread
uptake of NAC such as the fear of unnecessary chemotoxicity,
its perceived relatively modest survival benefit, and/or the fear
of a delay to radical treatment [4, 5]. Moreover, UCB is a
highly heterogeneous disease with varied response rates when
therapies are given in unselected patient populations. Identifi-
cation of the patients who are unlikely to respond to NAC
could allow better selection of patients to immediate radical
cystectomy or allocation of different systemic therapies such
as checkpoint inhibitors (CPI).
Modern medical decisions can be tailored to the indi-
vidual patient based on predicted response or risk of dis-
ease. Understanding the molecular basis of disease has
ushered in a new age of precision medicine. Molecular
markers are promising tools that may give insight into
which UCB patients will or will not benefit from neoadju-
vant systemic therapy (NAST) and which have the poten-
tial to overcome the limitations of conventionally used
prognostic risk factors. In addition, a biomarker-based
strategy to identify patients who should undergo NAC is
more cost-effective compared to the current unselected
use of NAC or radical cystectomy alone [6]. Numerous
publications provided data on potential molecular
markers associated with NAC response in UCB patients;
however, none is yet validated or widely used in the clini-
cal practice [7−9].
In this systematic review we aimed to summarize the
available evidence as well as to determine whether pretreat-
ment tissue-based biomarkers may help predict oncologic
and pathologic outcomes in patients treated with NAST for
UCB. This review is a benchmark for future developments.2. Evidence acquisition
2.1. Literature search
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews andMeta-analyses (PRISMA) statement [10]. This study’s proto-
col was registered a priori on the International Prospective
Register of Systematic Reviews (PROSPERO; Registration
ID CRD42020208417).
The PubMed, Web of Science, and Scopus databases
were searched in August 2020 to identify studies reporting
on the prognostic value of tissue-based biomarkers in
patients treated with NAST for UCB. A comprehensive
systematic literature search was independently performed
by two authors. The keywords used in our search strategy
included: (NAC OR neoadjuvant) AND (bladder OR
urothelial) AND (cancer OR tumor OR malignancy OR
carcinoma) AND (biomarker). In addition, we manually
searched for potentially relevant trials from the referen-
ces of selected studies. The primary outcome of interest
was both oncologic and pathologic outcomes in patients
treated with NAST for UCB.
After removing duplicates, two independent
reviewers screened the titles and abstracts. Any citation
which either reviewer thought should be included or
unclear for inclusion was identified for full text screen-
ing. Subsequently, reviewers reviewed full texts of
eligible articles for final inclusion and data extraction.
In cases of disagreement, the authors consulted with
the co-authors, and final decisions were reached by
consensus.2.2. Inclusion and exclusion criteria
We included all non-randomized observational studies
that reported on the prognostic value of tissue-based bio-
markers in UCB.
The PICO in this study was the following: patients
treated for UCB with detected pretreatment tissue-based
biomarkers. Intervention included NAST for UCB. Control
group included those patients without pretreatment tissue-
based biomarkers. The outcome included any measure of
association between oncologic and pathologic outcomes
and the candidate biomarker, the diagnostic performance of
the biomarker.
We excluded reviews, letters, editorials, animal studies,
study protocols, case reports, meeting abstracts, replies
from authors, brief correspondence, and articles not pub-
lished in English. Furthermore, we excluded the studies
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logic outcomes. References of all papers included were
scanned for additional studies of interest.2.3. Data extraction
Data extracted from each study were independently
extracted by two independent reviewers. Extracted data
included the following: first author’s name, publication
year, study design, demographics characteristics including
age range, sample size, pathological T stage, follow-up
duration, NAC regime, definition of response, type of bio-
markers, methods of biomarkers detection, % of patients
with high expression, and Main results. Subsequently, the
hazard ratios (HR) and 95% confidence intervals (CI) of tis-
sue-based biomarkers associated with each outcome were
retrieved.Figure 1. Flow diagram of the study selectio2.4. Evidence synthesis
The literature search identified 624 unique references.
Among them, 233 records were removed due to duplication,
and 261 articles were excluded due to unrelated outcomes
during the screening process (Figure 1). Of the 130 full-text
articles assessed for eligibility, 86 were excluded based on
the selection criteria.
Overall, 44 studies were finally included in the present
systematic review. Characteristics of the studies are shown
in Table 1. Fifteen of the included studies had a prospective
study design, and twenty-nine were retrospective.3. Immunohistochemistry (IHC)
Twenty-three studies provided data on the pretreatment
biomarkers detected at IHC.n procedure for the systematic review.
Table 1













Type of markers evaluated(cut off
values)
Methods % of high expression
(%)
Main results
Bandini, 2020 [27] P 112 66
(IQR 61-73)
T2-T4, N0 NR Pembrolizumab pT0N0 TMB (11 mut/Mb) CGP TMB (12.5) TMB was not associated with NAC response on
multivariable analysis (OR 1.04, 0.98-1.10,
p=0.09)
Baras, 2015 [42] R 37 63 (44−83) T2-T4 NR GC <ypT2 mRNAs (10%),
Ki67, p53, GDPD3, and SPRED1
IHC NR The combination of GDPD3 and SPRED1 predicted
NAC response (p<0.001)
Baras, 2016 [43] R 41 64 (45-82) T2-T4, N0/N+ NR NR <ypT2 PD-L1, CD8, FOXP3, the ratio of
CD8/FOXP3
IHC NR The ratio of CD8/FOXP3 TIL densities was strongly
associated with response (p=0.0003)
Choi, 2014 [23] R 18 NR T2-T4, N0/N+, M0/+ NR Platinum-based <pT1 Molecular subtypes: basal-like,





Response was 0% in p53-like, 40% - basal-like and
67% - luminal-like subtypes (p=0.018)
Choueiri, 2014 [16] P 31 NR T2-T4, N0-1, M0 2 years ddMVAC <pT1 ERCC1 (H score>0.1) IHC ERCC1 (39) 43% of ERCC1-positive and 60% of ERCC1-
negative patients achieved PR
de Jong, 2019 [44] R 223 62 (56−71) T2−4, N0-3, M0 NR NR NR lncRNA (LC1, LC2, LC3, LC4




Gene expression analysis FGFR3+ (16%) The luminal-papillary lncRNA cluster (LC3) tumors
had favorable prognosis and had enhanced
FGFR3, SHH, and wild-type p53 pathway activity.
Efstathiou, 2019 [24] R 223 61.7 T2-T4, N0, M0 3.5 year (IQR 2.1
- 5.0)





NR DSS and OS were worse among patients with
claudin-low tumors (p=0.01 and p=0.068,
respectively).
A stromal signature was associated with worse DSS
and OS (p=0.006 and p=0.015, respectively).
Font, 2011 [33] R 57 64 (41-80) T2-T4, N0/+, M0/+ 45 mo (14−190) GC, CMV pT0-1 BRCA1 (>26.77) RT-PCR BRCA1 (32) 60% of patients with low/intermediate BRCA1 levels
atteined PR vs 22% of those with high levels
(p=0.01).
Median OS was 168 mo in patients with low/
intermediate levels and 34 mo in patients with
high BRCA1 levels (P = 0.002).
Garcia del Muro, 2004
[18]
R 82 61 (30−74) T2-T4, N0, M0 55 mo MVAC, CMV, CbMV +
radiotherapy
≤ T1 p53 (20%),
p21 (20%),
pRB (10%)
IHC p53 (47), p21 (52), pRB
(67)
Positive p53 and p21 were independently associated
with decreased survival with bladder preservation
(both p<0.02).
DFS: positive p53 and p21 were independently
associated with decreased DFS (p<0.005 and
p<0.009, respectively).
OS: p53 overexpression was associated with poor OS
(p<0.03).
The positive expression of combination p53 and p21
was a strong and unfavorable prognostic factor for
survival with bladder preservation (p<0.006), DFS
(p<0.003), and OS (p<0.02).
Groenendijk, 2016 [36] P 94 NR NR NR GC, GCb, MVAC ypT0N0 178 cancer- associated genes NGS NR ERBB2 mutations are strongly associated with
response (p=0.006), whereas ERCC2 mutations
are not.
Grossman, 2006 [12] P 94 64 (39-80) T2-T4a, N0, M0 NR MVAC NR Ki67
(1000 cells),
p53 (20%), angiogenesis
IHC NR Ki67 expression was not associated with PFS (HR
0.62; 95% CI 0.37-1.03; p=0.063) and OS (HR
0.74; 95% CI 0.44-1.24; p=0.25).
p53 expression was not associated with worse PFS
(HR=1.02; 95% CI 0.61-1.71; p=0.93) and OS
(HR 1.48; 95% CI 0.87-2.53; p=0.15).
Angiogenesis was not associated with PFS (HR 1.0;
95% CI 0.62-1.64; p=0.99) and OS (HR1.04; 95%
CI 0.63-1.70; p=0.89).
Hemdan, 2015 [19] R 125 66 T1G3, T2−T4, Nx, M0 NR Cisplatin/ methotrexate or
doxorubicin +
radiotherapy
pT0 or Ta/CIS Emmprin and survivin IHC Emmprin (28),
surviving (50)
OS: negative emmprin expression had significantly
greater OS (71% vs 38%, p <0.001).
CSS: in negative and positive emmprin expression
was 76% vs 56% (p=0.027).
Hemdan, 2018 [45] R 177 NR T1G3, T2−T4, Nx, M0 NR Cisplatin/ methotrexate pT0 or Ta/CIS CCT-a (20%) IHC CCT-a (24) Improved OS with NAC treatment only in the CCT-
a-negative group (p=0.006).
No difference was found in the CCT-a-positive group
(p=0.9).
Hensley, 2019 [46] R 69 NR T2 NR MVAC, GC ypT0N0 E-cadherin (125), N-cadherin
(34.7),
b-catenin (125), vimentin (50.3),
IHC NR Extravesical disease showed increased N-cadherin
(p= 0.004), increased vimentin (p=0.028),
increased b-catenin (p= 0.019), decreased P-cofilin
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Several studies in patients undergoing NAC demon-
strated a correlation between pretreatment p53 (cell-cycle
marker) overexpression at IHC and worse survival out-
comes. For example, Sarkis et al. found that at 5.8 years
after NAC, 41% of patients with p53 overexpression and
77% - without overexpression (p=0.007) experienced death
[11]. In contrast, Grossman et al. [12] reported that p53
expression was not associated with progression free (PFS)
(HR=1.02; 95% CI 0.61-1.71; p=0.93) or overall (OS) sur-
vival (HR 1.48; 95% CI 0.87-2.53; p=0.15). Similarly, Ki-
67 (proliferation marker) expression was associated with
neither PFS (HR 0.62; 95% CI 0.37-1.03; p=0.063) nor OS
(HR 0.74; 95% CI 0.44-1.24; p=0.25). Conversely, in a
study comprising 130 patients, Rubino et al. [13] found that
positive Ki-67 expression was associated with worse OS
(HR 2.412, 95% CI, 1.076−5.408) as well as the absence of
complete pathological response (p<0.001) and tumor down-
staging (p<0.001). Interestingly, positive PD-L1 was asso-
ciated with a lack of complete pathological response
(OR = 0.16; 95% CI, 0.05−0.59; p=0.006) and tumor down-
staging (OR = 0.29; 95% CI, 0.13−0.67; p=0.003) in 130
patients treated with NAC [13]. High infiltration of PD-1 in
tumor was shown to be associated with the longest time to
recurrence (all<0.05) [14].
3.2. DNA repair pathway alterations
A study assessing DNA repair pathway alterations found
that a strong expression of ERCC1 was associated with
pathological response in patients treated with neoadjuvant
gemcitabine and cisplatin (GC) (p=0.01) [15]. Choueiri et
al. [16] reported a pathological response (<pT1) rate of
43% in ERCC1-positive and 60% in ERCC1- negative
UCB patients treated with dose dense MVAC.
3.3. Receptor tyrosine kinases
Yang et al. [15] reported that receptor tyrosine kinases
(ERBB2, FGFR3, and PIK3CA) were more commonly
altered in the responders (p<0.01) compared to the non-res-
ponders; FGFR3 mutations were significantly enriched in
patients with a response to GC based regimen (p=0.01). In
contrast, Kiss et al. [17] failed to report on the association
between ERBB2 alterations and both pathological response
(<ypT2N0) or OS.
3.4. Biomarkers for combination of NAC and radiotherapy
Three studies reported IHC biomarkers in patients
treated with combination of NAC and radiotherapy [18]
−[20]. Positive p53 and p21 were independently associated
with decreased disease free survival (DFS) in a retrospec-
tive study of 82 patients (p<0.005 and p<0.009, respec-
tively); additionally, p53 overexpression was associated
E. Laukhtina et al. / Urologic Oncology: Seminars and Original Investigations 39 (2021) 180−190 187with poor OS (p<0.03) [18]. Alteration of the combination
of p53 and p21 was a strong and unfavorable prognostic
factor for both DFS (p<0.003) and OS (p<0.02). Hemdan
et al. [19] demonstrated that patients with negative emm-
prin (extracellular matrix metalloproteinase inducer)
expression had significantly greater OS in 125 UCB
patients treated with radiotherapy and NAC (71% vs. 38%,
p <0.001); cancer specific survival (CSS) in patients with
negative and positive emmprin expression was 76% and
56%, respectively (p=0.027). Turker et al. [20] reported
that patients exhibiting Bcl-2 negative expression had a sig-
nificantly increased OS (p=0.009). In summary, pretreat-
ment p53, p21, emmprin, and Bcl-2 have been suggested to
exhibit predictive value in UCB patients treated with NAC
and radiotherapy. However, further studies are needed to
improve our understanding of the radiotherapy impact on
inflammation status, which could affect biomarker expres-
sion.
According to the currently available literature, IHC bio-
markers, including receptor tyrosine kinases and DNA
repair pathway alterations, do not seem to clearly improve
our prediction of pathological response or oncologic out-
comes in UCB patients treated with NAC.
4. Gene expression and genomic DNA analyses
Nineteen studies provided data on the pretreatment bio-
markers detected using gene expression analysis.
Over the last decade, molecular subtyping has led to dis-
tinct or partially overlapping molecular classifications of
UCB. The arising molecular subtypes based on these
classifications have been shown to be clinically useful in
predicting the likelihood of therapy response. Whole tran-
scriptome analysis suggests that luminal and basal tumors,
compared to claudin-low or luminal-infiltrated tumors,
might have the best response to platinum-based NAC
(p<0.05) [21, 22]. Supporting this data, Choi et al. [23]
reported response rate of 0% in p53-like, 40% - basal-like,
and 67% - luminal-like subtypes (p=0.018). Efstathiou et
al. [24] detected worse DSS and OS among patients with
claudin-low tumors at transcriptome-wide gene expression
profile analysis (p=0.01 and p=0.068, respectively). Taking
together, luminal and basal tumor subtypes showed better
NAC response, while claudin-low and luminal-infiltrated
tumor subtypes did not.
Surprisingly, during comprehensive genomic profiling,
molecular subtypes were not significantly associated with
response (ypT0N0) in both studies assessing NAC and
Pembrolizumab (all p>0.2) [25]. Notably, immune signa-
tures explored in this study had a significant association
with the pathologic response in the PURE-01 cohort (all
p<0.02), but not in the NAC cohort (p>0.7) [25]. Among
other studies on predictive biomarkers for neoadjuvant
immunotherapy, Necchi et al. [26] reported an association
of tumor mutational burden (TMB) and PD-L1 combined
positive score with both the pT0 and the pT1 response toPembrolizumab (all p<0.03). In contrast, Bandini et al. [27]
found that TMB was not associated with response (pT0N0)
to Pembrolizumab on multivariable analysis (OR 1.04,
0.98-1.10, p=0.09). These results were supported by Powles
et al. [28] in a study of 95 patients treated with neoadjuvant
Atezolizumab. Summing up, in terms of neoadjuvant
immune-checkpoint inhibitors (CPI), PD-L1 seems to main-
tain value as a predictive biomarker, while the utility of
TMB and molecular subtypes is still controversial.
Among other predictive biomarkers detected with gene
expression analysis, Plimack et al. analyzed molecular
alterations in baseline tumor samples and did not find a cor-
relation between p53 deleterious mutations and response to
NAC [29]. Defects in DNA repair genes (ATM, RB1, and
FANCC) were shown to predict pathological response in
both MVAC (p<0.001) and dose dense GC (p = 0.033)
cohorts and at the same time with better OS after MVAC
(p = 0.007) [30]. Another DNA repair pathway alteration
(ERCC2) was also significantly mutated in cisplatin res-
ponders compared to non-responders (p<0.01) [31]. In con-
trast, genetic alterations in genes associated with cell cycle
checkpoints and regulators (E2F3, JUN, FBXW7) sug-
gested potential resistance [32].
Summing up, according to the currently available litera-
ture, alterations in DNA repair genes seem useful to predict
pathological response and even oncologic outcomes in
UCB patients treated with NAC. However, these data
should be supported by future large-scale trials.
5. Polymerase chain reaction (PCR)
Three studies provided data on the pretreatment bio-
markers detected at quantitative PCR [33]−[35].
In order to investigate the predictive role of the breast
cancer susceptibility gene 1 (BRCA1) mRNA expression in
UCB, tumor samples of 57 patients treated with GC or
CMV (cisplatin, methotrexate, vinblastine) for UCB were
retrospectively analyzed using quantitative PCR [33]. 66%
of patients with low/intermediate BRCA1 levels attained a
pathological response (pT0-1) compared to 22% of those
with high BRCA1 levels. Furthermore, median survival
was longer in patients with low BRCA1 expression (168
and 34 months, respectively, p=0.002). Thus, BRCA1
expression could be a useful tool for selecting UCB patients
who are likely to benefit from cisplatin-based NAC. The
authors suggested that taxane-based therapy for patients
with high BRCA1 expression could be explored in further
studies.
Among studies on other tissue-based biomarkers
detected with PCR, Kato et al. [34] identified 12 candidates
genes tested in tissue microarrays derived from baseline
biopsies of 37 patients treated with NAC. Among these
genes, IPO-7 and SLC22A18 were upregulated in non-res-
ponders. Vinall et al. [35] found that higher let-7c expres-
sion had higher odds of responding (OR 2.493, 95% CI
1.121-5.546, p=0.023), and let-7c levels allowed predicting
188 E. Laukhtina et al. / Urologic Oncology: Seminars and Original Investigations 39 (2021) 180−190response (pT0) with an accuracy of 72%. Nevertheless,
larger scale studies are certainly warranted to confirm and
validate these results.
In general, quantitative PCR results for the expression of
genes selected through microarray analysis might correctly
classify cases with regard to their NAC response.
6. Next-generation sequencing (NGS)
Two studies provided data on the pretreatment bio-
markers detected at NGS [36, 37].
In a study of Groenendijk et al. [36], ERBB2 was
strongly associated with NAC response, defined as ypT0N0
(p=0.006), whereas ERCC2 mutations were not. Miron et
al. [37] found that mutations in ATM, RB1, or FANCC
were significantly associated with improved OS (p=0.0043)
and DSS (p=0.0015) in 58 patients treated with NAC (GC
or MVAC). The authors hypothesized that, based on under-
standing the function of ATM, RB1, and FANCC and their
involvement in DNA damage repair, mutations in these
genes sensitize tumors to cisplatin because of a baseline
deficiency in DNA repair.
7. Discussion
This review on the impact of using pretreatment tissue-
based biomarkers to select patients who are most likely to
benefit from NAST generated several important findings.
First of all, there is no clear benefit of using predictive bio-
markers, including receptor tyrosine kinases and DNA repair
pathway alterations, detected at IHC to predict pathologic
response or oncologic outcomes in UCB patients treated with
NAC. The controversial results can be explained by the small
sample size as well as the retrospective nature of most
included studies, leading to heterogeneity between NAST
cohorts, differences between NAC settings, and definitions
such as that of pathologic response as well as non-standard-
ized sample collections and arbitrary cut-offs during assay
analysis. Moreover, we believe that for the initial development
of a putative marker model as well as markers with combina-
tions, it is essential to reflect the molecular understanding of
the tumor and its microenvironment.
We found out that specific genomic alterations in DNA
repair genes (e.g., ATM, RB1, FANCC, and ERCC2) pro-
vide predictive value for predicting pathologic response
and oncologic outcomes after NAC. Quantitative PCR
results for the expression of genes selected through micro-
array analysis (e.g., BRCA1) could correctly classify cases
with regard to their NAC response. However, it should be
stressed that the utility of genetic profiling has historically
been limited to small gene panels and costly molecular
diagnostics. Hence, biomarkers detected at IHC can still be
a simple and less expensive alternative. To facilitate inclu-
sion into routine urological practice, precise identification
of tissue-based biomarkers with accurate detection technol-
ogy seems to be of necessity. The continuous improvementin high throughput technologies, the development of novel
analytical tools based on artificial intelligence need for bio-
marker-driven preclinical and clinical trials. Nowadays,
NGS is becoming a complementary diagnostic tool, guiding
the decision-making progress with the goal of facilitating
precision medicine. We believe that with the incorporation
of NGS, physicians will have the ability to obtain a more
comprehensive understanding of the molecular alterations
driving an individual urothelial cancer [38].
In terms of predicting the likelihood of responding to
neoadjuvant CPI, TURBT PD-L1 seems to have value as an
accurate but not ideal biomarker [39]. Indeed, a higher path-
ologic response rate was shown in patients with PD-L1 pos-
itive tumors compared to those with PD- L1 negative
tumors; while the utility of TMB or molecular subtypes in
patients treated with neoadjuvant CPI is still unclear, at
best. Moreover, it was recently shown that indicate molecu-
lar subtypes may not be useful due to tumor heterogeneity
and various models of changes in molecular profiles before
or during progression [40, 41]. Understanding the stability
of molecular subtypes over time and the subtype heteroge-
neity within tumors and patients remains challenging.
Future areas certainly include conceptual molecular path-
ways (e.g., FGFR3 pathway) that would allow for targeted
therapy approaches. New clinical trials that use molecularly
guided therapy selection will determine the clinical efficacy
of the integration of genomics and other molecular predic-
tive biomarkers to guide daily therapeutic decision-making.
Our systematic review is not free from limitations. First,
the inconsistencies in evaluation of the tissue-based bio-
markers among the enrolled trials could lead to potential
confounding and bias. The second limitation is the retro-
spective and heterogeneous nature of most included studies
which also suffered from single-center designs. Third, the
small cohort size of most of the included studies may have
limited their power to detect a statistically and/or clinically
significant associations. Therefore, well-designed compara-
tive trials with larger cohorts are required to validate some
of the most promising findings inherent to the present sys-
tematic review.8. Conclusions
Pretreatment tissue-based biomarkers still hold promise
in selecting the ideal UCB patient who is most likely to ben-
efit from NAST. However, due to the lack of prospective,
well-designed, large scale data, no molecular biomarkers
could be recommended for the routine use. The present sys-
tematic review offers a robust framework to enable the test-
ing and validation of predictive biomarkers in future
prospective clinical trials.Ethical standards
Not applicable.
E. Laukhtina et al. / Urologic Oncology: Seminars and Original Investigations 39 (2021) 180−190 189Declaration of Competing Interest
None
Acknowledgements
Ekaterina Laukhtina and Victor M. Schuettfort are sup-
ported by the EUSP Scholarship of the European Associa-
tion of Urology (EAU). Nico C. Grossmann is supported by
the Zurich Cancer League.
References
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA. Cancer
J. Clin. 2019. https://doi.org/10.3322/caac.21551.
[2] Witjes JA, et al. EAU Guidelines on Muscle-invasive and Metastatic
Bladder Cancer. Edn. presented at the EAU Annual Congress
Amsterdam. EAU Guidelines Office 2020:2020.
[3] Witjes JA, et al. EAU-ESMO Consensus Statements on the Manage-
ment of Advanced and Variant Bladder Cancer—An International
Collaborative Multistakeholder Efforty[Formula presented]: Under
the Auspices of the EAU-ESMO Guidelines Committees. Eur. Urol.,
2020. https://doi.org/10.1016/j.eururo.2019.09.035.
[4] Rosenblatt R, et al. Pathologic downstaging is a surrogate marker for
efficacy and increased survival following neoadjuvant chemotherapy
and radical cystectomy for muscle-invasive urothelial bladder cancer.
Eur. Urol. 2012. https://doi.org/10.1016/j.eururo.2011.12.010.
[5] Eulitt PJ, Bjurlin MA, Milowsky MI. Perioperative systemic therapy
for bladder cancer. Current Opinion in Urology 2019. https://doi.org/
10.1097/MOU.0000000000000600.
[6] Lotan Y, Woldu SL, Sanli O, Black P, Milowsky MI. Modelling cost-
effectiveness of a biomarker-based approach to neoadjuvant chemo-
therapy for muscle-invasive bladder cancer. BJU Int 2018. https://
doi.org/10.1111/bju.14220.
[7] Buttigliero C, Tucci M, Vignani F, Scagliotti GV, Di Maio M. Molec-
ular biomarkers to predict response to neoadjuvant chemotherapy for
bladder cancer. Cancer Treatment Reviews 2017. https://doi.org/
10.1016/j.ctrv.2017.01.002.
[8] Tse J, Ghandour R, Singla N, Lotan Y. Molecular predictors of com-
plete response following neoadjuvant chemotherapy in urothelial car-
cinoma of the bladder and upper tracts. International Journal of
Molecular Sciences 2019. https://doi.org/10.3390/ijms20040793.
[9] Ilijazi D, Abufaraj M, Hassler MR, Ertl IE, D’Andrea D, Shariat SF.
Waiting in the wings: the emerging role of molecular biomarkers in
bladder cancer. Expert Review of Molecular Diagnostics 2018.
https://doi.org/10.1080/14737159.2018.1453808.
[10] Liberati A, et al. The PRISMA statement for reporting systematic
reviews and meta-analyses of studies that evaluate health care inter-
ventions: Explanation and elaboration. PLoS Medicine 2009. https://
doi.org/10.1371/journal.pmed.1000100.
[11] Sarkis AS, et al. Prognostic value of p53 nuclear overexpression in
patients with invasive bladder cancer treated with neoadjuvant MVAC.
J. Clin. Oncol. 1995. https://doi.org/10.1200/JCO.1995.13.6.1384.
[12] Grossman HB, et al. Evaluation of Ki67, p53 and angiogenesis in
patients enrolled in a randomized study of neoadjuvant chemotherapy
with or without cystectomy: A Southwest Oncology Group study.
Oncol Rep 2006;16(4):807–10.
[13] Rubino S, et al. Positive Ki-67 and PD-L1 expression in post-neoad-
juvant chemotherapy muscle-invasive bladder cancer is associated
with shorter overall survival: a retrospective study. World J. Urol.
Jul. 2020. https://doi.org/10.1007/s00345-020-03342-5.
[14] Wahlin S, Nodin B, Leandersson K, Boman K, Jirstr€om K. Clinical
impact of T cells, B cells and the PD-1/PD-L1 pathway in muscleinvasive bladder cancer: a comparative study of transurethral resec-
tion and cystectomy specimens. Oncoimmunology 2019;8(11).
https://doi.org/10.1080/2162402X.2019.1644108.
[15] Yang Z, et al. Somatic FGFR3 Mutations Distinguish a Subgroup of
Muscle-Invasive Bladder Cancers with Response to Neoadjuvant
Chemotherapy. EBioMedicine 2018;35:198–203. https://doi.org/
10.1016/j.ebiom.2018.06.011.
[16] Choueiri TK, et al. Neoadjuvant dose-dense methotrexate, vinblas-
tine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-
invasive urothelial cancer: pathologic, radiologic, and biomarker cor-
relates. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014;32
(18):1889–94. https://doi.org/10.1200/JCO.2013.52.4785:Jun.
[17] Kiss B, et al. Her2 alterations in muscle-invasive bladder cancer:
Patient selection beyond protein expression for targeted therapy. Sci.
Rep. 2017;7:42713.. https://doi.org/10.1038/srep42713:Feb.
[18] Garcia del Muro X, et al. p53 and p21 Expression levels predict organ
preservation and survival in invasive bladder carcinoma treated with
a combined-modality approach. Cancer 2004;100(9):1859–67.
https://doi.org/10.1002/cncr.20200:May.
[19] Hemdan T, Malmstr€om P-U, Jahnson S, Segersten U. Emmprin Expres-
sion Predicts Response and Survival following Cisplatin Containing
Chemotherapy for Bladder Cancer: A Validation Study. J. Urol.
2015;194(6):1575–81. https://doi.org/10.1016/j.juro.2015.06.085:Dec.
[20] Turker P, Segersten U, Malmstr€om P-U, Hemdan T. Is Bcl-2 a predic-
tive marker of neoadjuvant chemotherapy response in patients with uro-
thelial bladder cancer undergoing radical cystectomy?,” Scand. J. Urol.
2019;53(1):45–50. https://doi.org/10.1080/21681805.2019.1575467:
Feb.
[21] Seiler R, et al. Impact of Molecular Subtypes in Muscle-invasive
Bladder Cancer on Predicting Response and Survival after Neoadju-
vant Chemotherapy. Eur. Urol. 2017;72(4):544–54. https://doi.org/
10.1016/j.eururo.2017.03.030:Oct.
[22] Seiler R, et al. Divergent Biological Response to Neoadjuvant Che-
motherapy in Muscle-invasive Bladder Cancer. Clin. cancer Res. an
Off. J. Am. Assoc. Cancer Res. 2019;25(16):5082–93. https://doi.
org/10.1158/1078-0432.CCR-18-1106:Aug.
[23] Choi W, et al. Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to front-
line chemotherapy. Cancer Cell 2014;25(2):152–65. https://doi.org/
10.1016/j.ccr.2014.01.009:Feb.
[24] Efstathiou JA, et al. Impact of Immune and Stromal Infiltration on
Outcomes Following Bladder-Sparing Trimodality Therapy for Mus-
cle-Invasive Bladder Cancer(Figure presented. Eur. Urol. 2019;76
(1):59–68. https://doi.org/10.1016/j.eururo.2019.01.011.
[25] Necchi A, et al. Impact of Molecular Subtyping and Immune Infiltra-
tion on Pathological Response and Outcome Following Neoadjuvant
Pembrolizumab in Muscle-invasive Bladder Cancer[Formula pre-
sented]. Eur. Urol. 2020;77(6):701–10. https://doi.org/10.1016/j.eur-
uro.2020.02.028.
[26] Necchi A, et al. Updated Results of PURE-01 with Preliminary Activity
of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Blad-
der Carcinoma with Variant Histologies. Eur. Urol. 2020;77(4):439–46.
https://doi.org/10.1016/j.eururo.2019.10.026:Apr.
[27] Bandini M, et al. Predicting the pathologic complete response after
neoadjuvant pembrolizumab in muscle-invasive bladder cancer. J.
Natl. Cancer Inst. 2020. https://doi.org/10.1093/jnci/djaa076:Jun..
[28] Powles T, et al. Clinical efficacy and biomarker analysis of neoadju-
vant atezolizumab in operable urothelial carcinoma in the ABACUS
trial. Nat Med 2019;25(11):1706–14. https://doi.org/10.1038/s41591-
019-0628-7.
[29] Plimack ER, et al. Accelerated methotrexate, vinblastine, doxorubi-
cin, and cisplatin is safe, effective, and efficient neoadjuvant treat-
ment for muscle-invasive bladder cancer: results of a multicenter
phase II study with molecular correlates of response and toxicity. J.
Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014;32(18):1895–901.
https://doi.org/10.1200/JCO.2013.53.2465:Jun.
190 E. Laukhtina et al. / Urologic Oncology: Seminars and Original Investigations 39 (2021) 180−190[30] Plimack ER, et al. Defects in DNA Repair Genes Predict Response to
Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive
Bladder Cancer. Eur. Urol. 2015;68(6):959–67. https://doi.org/
10.1016/j.eururo.2015.07.009:Dec.
[31] Van Allen EM, et al. Somatic ERCC2 mutations correlate with cis-
platin sensitivity in muscle-invasive urothelial carcinoma. Cancer
Discov 2014. https://doi.org/10.1158/2159-8290.CD-14-0623.
[32] Liu D, et al. Mutational patterns in chemotherapy resistant muscle-
invasive bladder cancer. Nat. Commun. 2017;8(1):2193.. https://doi.
org/10.1038/s41467-017-02320-7:Dec.
[33] Font A, et al. BRCA1 mRNA expression and outcome to neoadjuvant
cisplatin-based chemotherapy in bladder cancer. Ann. Oncol. 2011.
https://doi.org/10.1093/annonc/mdq333.
[34] Kato Y, et al. Predicting response of bladder cancers to gemcitabine
and carboplatin neoadjuvant chemotherapy through genome-wide
gene expression profiling. Exp. Ther. Med. 2011. https://doi.org/
10.3892/etm.2010.166.
[35] Vinall RL, et al. Decreased expression of let-7c is associated with
non-response of muscle-invasive bladder cancer patients to neoadju-
vant chemotherapy. Genes Cancer 2016;7(3−4):86–97. https://doi.
org/10.18632/genesandcancer.103:Mar.
[36] Groenendijk FH, et al. ERBB2 Mutations Characterize a Subgroup of
Muscle-invasive Bladder Cancers with Excellent Response to Neoad-
juvant Chemotherapy. Eur. Urol. 2016;69(3):384–8. https://doi.org/
10.1016/j.eururo.2015.01.014:Mar.
[37] Miron B, et al. Defects in DNA Repair Genes Confer Improved
Long-term Survival after Cisplatin-based Neoadjuvant Chemother-
apy for Muscle-invasive Bladder Cancer. Eur. Urol. Oncol. 2020.
https://doi.org/10.1016/j.euo.2020.02.003:Mar.
[38] Hassler MR, et al. Molecular Characterization of Upper Tract Urothe-
lial Carcinoma in the Era of Next-generation Sequencing: A System-
atic Review of the Current Literature. European Urology 2020.
https://doi.org/10.1016/j.eururo.2020.05.039.
[39] Bensalah K, Montorsi F, Shariat SF. Challenges of Cancer Biomarker
Profiling. Eur. Urol. 2007. https://doi.org/10.1016/j.eururo.2007.09.036.
[40] Morera DS, et al. Clinical Parameters Outperform Molecular Sub-
types for Predicting Outcome in Bladder Cancer: Results from Multi-
ple Cohorts, Including TCGA. J. Urol. 2020. https://doi.org/10.1097/
JU.0000000000000351.
[41] Sj€odahl G, et al. Molecular changes during progression from non-
muscle invasive to advanced urothelial carcinoma. Int. J. Cancer
2020. https://doi.org/10.1002/ijc.32737.
[42] Baras AS, et al. Identification and Validation of Protein Biomarkers
of Response to Neoadjuvant Platinum Chemotherapy in Muscle Inva-
sive Urothelial Carcinoma. PLoS One 2015;10(7):e0131245. https://
doi.org/10.1371/journal.pone.0131245.
[43] Baras AS, et al. The ratio of CD8 to Treg tumor-infiltrating lympho-
cytes is associated with response to cisplatin-based neoadjuvant che-
motherapy in patients with muscle invasive urothelial carcinoma of
the bladder. Oncoimmunology 2016;5(5):e1134412. https://doi.org/
10.1080/2162402X.2015.1134412:May.
[44] De Jong JJ, et al. Long non-coding RNAs identify a subset of luminal
muscle-invasive bladder cancer patients with favorable prognosis.
Genome Med 2019;11(1). https://doi.org/10.1186/s13073-019-0669-z.[45] Hemdan T, Turker P, Malmstr€om P-U, Segersten U. Choline-phos-
phate cytidylyltransferase-a as a possible predictor of survival and
response to cisplatin neoadjuvant chemotherapy in urothelial cancer
of the bladder. Scand. J. Urol. 2018;52(3):200–5. https://doi.org/
10.1080/21681805.2018.1439527:Jun.
[46] Hensley PJ, et al. Predictive value of phenotypic signatures of bladder
cancer response to cisplatin-based neoadjuvant chemotherapy. Urol.
Oncol. 2019;37(9). https://doi.org/10.1016/j.urolonc.2019.06.020:572.
e1-572.e11Sep.
[47] Kilari D, et al. Copper Transporter-CTR1 Expression and Pathologi-
cal Outcomes in Platinum-treated Muscle-invasive Bladder Cancer
Patients. Anticancer Res 2016;36(2):495–501:Feb..
[48] Nomura S, et al. Snail expression and outcome in T1 high-grade and T2
bladder cancer: a retrospective immunohistochemical analysis. BMC
Urol 2013;13:73.. https://doi.org/10.1186/1471-2490-13-73:Dec.
[49] Nomura S, et al. Dual-specificity tyrosine phosphorylation-regulated
kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 blad-
der cancer patients receiving neoadjuvant chemotherapy. BMC Urol
2015;15:53.. https://doi.org/10.1186/s12894-015-0040-7:Jun.
[50] Ornstein MC, et al. Myeloid-derived suppressors cells (MDSC) corre-
late with clinicopathologic factors and pathologic complete response
(pCR) in patients with urothelial carcinoma (UC) undergoing cystec-
tomy. Urol. Oncol. 2018;36(9):405–12. https://doi.org/10.1016/j.uro-
lonc.2018.02.018:Sep.
[51] Pal SK, et al. Prognostic Significance of Neutrophilic Infiltration in
Benign Lymph Nodes in Patients with Muscle-invasive Bladder Can-
cer. Eur. Urol. Focus 2017;3(1):130–5. https://doi.org/10.1016/j.
euf.2016.03.003:Feb.
[52] Pichler R, et al. Amplification of 7p12 Is Associated with Pathologic
Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive
Bladder Cancer. Am. J. Pathol. 2020;190(2):442–52. https://doi.org/
10.1016/j.ajpath.2019.10.018:Feb.
[53] Takata R, et al. Predicting response to methotrexate, vinblastine,
doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder
cancers through genome-wide gene expression profiling. Clin. Cancer
Res. 2005. https://doi.org/10.1158/1078-0432.CCR-04-1988.
[54] Takata R, et al. Validation study of the prediction system for clinical
response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007.
https://doi.org/10.1111/j.1349-7006.2006.00366.x.
[55] Tervahartiala M, et al. Immunological tumor status may predict
response to neoadjuvant chemotherapy and outcome after radical cys-
tectomy in bladder cancer. Sci. Rep. 2017;7(1). https://doi.org/
10.1038/s41598-017-12892-5.
[56] Williams PD, et al. Concordant gene expression signatures predict
clinical outcomes of cancer patients undergoing systemic therapy.
Cancer Res 2009. https://doi.org/10.1158/0008-5472.CAN-09-0798.
[57] Winters BR, et al. Mechanistic target of rapamycin (MTOR) protein
expression in the tumor and its microenvironment correlates with more
aggressive pathology at cystectomy. Urol. Oncol. Semin. Orig. Investig.
2018;36(7). https://doi.org/10.1016/j.urolonc.2018.03.016:342.e7-342.
e14.
[58] Xylinas E, et al. An Epigenomic Approach to Improving Response to
Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomole-
cules 2016;6(3). https://doi.org/10.3390/biom6030037:Sep.
